Press Release

CD BIOSCIENCES INTRODUCES NEW SOLUTIONS TO SUPPORT CELL DEATH STUDIES



CD BioSciences recently launched a comprehensive panel of research solutions covering all aspects of cell death studies.

FOR IMMEDIATE RELEASE

02/03/2023

CD BioSciences, a US-based CRO serving the global life science research community, recently launched a comprehensive panel of research solutions covering all aspects of cell death studies, particularly Type I Cell Death, from Mechanism Study, Phenotype Analysis, Chemical Screening, Regulator Identification, to Regulator Characterization.

In multicellular organisms, cell death is the result of terminated cellular functions. Thus it is essential for maintaining tissue homeostasis and eliminating potentially harmful cells. Characterized by distinct morphologies, apoptosis, autophagic cell death, and necrosis are the three major types of cell death. Meanwhile, they are executed through distinct but sometimes overlapping signaling pathways in response to specific stimuli. Although cell death can be caused by overwhelming damage, most are the result of specific signaling events.

Apoptosis or type I cell death is a process of programmed cell death characterized by cell shrinkage, membrane blebbing, global mRNA decay, and chromatin condensation (pyknosis). It is also defined as cell death accompanied by caspase protease activation. The main signaling pathways that trigger apoptotic cell death are the mitochondrial pathway (the intrinsic) and the death receptor pathway (the extrinsic).

Apoptosis is an essential part of various processes such as normal cell turnover, immune response, and embryonic development. Inappropriate apoptosis is associated with many human diseases, including neurodegenerative diseases, ischemic injuries, autoimmune diseases, and various cancers.

As cell death is closely related to diseases, in-depth characterization of cell death events may uncover new therapeutic targets. As a trusted CRO, CD BioSciences now provides comprehensive solutions covering all aspects of life science research, including Type I Cell Death, ranging from Mechanism Study, Phenotype Analysis, Chemical Screening, Regulator Identification, to Regulator Characterization.

Mechanism Study involves the investigation of mechanisms for certain regulators. Phenotype Analysis analyzes cellular phenotypes regulated by genes and/or proteins of interest. Chemical Screening examines inhibitors or activators of certain cell deaths. Regulator Identification identifies gene regulators participating in a certain cell death signaling pathway. Regulator Characterization studies molecular functions of certain regulators in cell death signaling pathways.

CD BioSciences is dedicated to assisting life science researchers focusing on cell death studies. For customers interested in more information regarding cell death solutions or other signaling pathways, please visit CD BioSciences at https://www.cd-biosciences.com.

About CD BioSciences

CD BioSciences is a trusted research product supplier and CRO based in New York. With high-quality reagents and comprehensive services, CD BioSciences is a one-stop shop devoted to advancing signaling pathway studies for researchers. The company is committed to fulfilling all demands in the research of signaling pathways and provides high-quality reagents and comprehensive solutions to support innovative discoveries.

Tags:
Type I Cell Death  |    |  

---

Organisation Profile:
CD BioSciences is a trusted research product supplier and CRO based in New York. With high-quality reagents and comprehensive services, CD BioSciences is the one-stop shop devoted to researchers making advancements in signaling pathway studies.






Press release contact details for CD BioSciences

NameCD BioSciences
Tel
Fax
Email
Websitehttps://www.cd-biosciences.com/
OrganisationCD BioSciences
Address
Town
County
Postcode




Other press releases from CD BioSciences

CD BioSciences Introduces New Solutions to Support Cell Death Studies
CD BioSciences Launches Scaffold-Based Technologies for 3D Cell Culture
CD BioSciences Launches Hyperspectral Imaging Technology for Food Safety
CD BioSciences Introduces New Cell Death Solutions to Facilitate Research
CD BioSciences Launches Fluorescence Correlation Spectroscopy
CD BioSciences Introduces Various Solutions for Studying Apoptotic Cell Death
CD BioSciences Launches Nanoparticles Imaging Technology for Scientists
CD BioSciences Introduces Multiple Solutions for Type II Cell Death Research
CD BioSciences Launches New Time-Lapse Imaging Services for Scientists
CD BioSciences Launches New Solutions for Microautophagy Research
CD BioSciences Announces New Immunofluorescence-Based Services
CD BioSciences Launches New Solutions for Type III Cell Death Research
CD BioSciences Launches New Super-Resolution Imaging Technology for Biomedical Research
CD BioSciences Announces New Research Solutions on Mitotic Catastrophe
CD BioSciences Announces New Single Molecule Fluorescence Imaging Technology
CD BioSciences Introduces New Metabolic Homeostasis Research Solutions
CD BioSciences Launches New Services to Study Catabolism in Diabetes
CD BioSciences Launches New 3D Tissue Imaging Services
HighRun DataScience Launches Data Science Platform for Global Customers
CD BioSciences Announces New Solutions for Studying Anabolism
CD Biosciences Introduces 3D Image Analysis Services For Bioimaging Research
CD BioSciences Expands Portfolio with Wide Range of Embedding Resins and Kits for Electron and Light Microscopy
CD BioSciences Announces New Solutions for Glucose Homeostasis Research
CD Biosciences Announces Expanded Capabilities for Mechanistic Target of Rapamycin Research in Diabetes and Metabolism
CD Biosciences Launches Substrate-Chromogens for Immunohistochemistry
CD BioSciences Launches New Range of In Vivo Imaging Reagents for Scientific Research
CD BioSciences Introduces IHC Ancillaries for Enhanced Research and Diagnostics
CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays

Disclaimer:
Issuers of the press releases are solely responsible for the content of their press releases. Connect2business.co.uk cannot be held liable for the content posted by others to this website.